• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Prevalence of Taste and Smell Dysfunction in Coronavirus Disease 2019.2019 年冠状病毒病味觉和嗅觉功能障碍的流行情况。
JAMA Otolaryngol Head Neck Surg. 2020 Aug 1;146(8):723-728. doi: 10.1001/jamaoto.2020.1155.
2
Evolution of Altered Sense of Smell or Taste in Patients With Mildly Symptomatic COVID-19.轻度症状 COVID-19 患者嗅觉或味觉改变的演变。
JAMA Otolaryngol Head Neck Surg. 2020 Aug 1;146(8):729-732. doi: 10.1001/jamaoto.2020.1379.
3
Recovery rate and factors associated with smell and taste disruption in patients with coronavirus disease 2019.新冠病毒 2019 患者嗅觉和味觉障碍的恢复率及其相关因素。
Am J Otolaryngol. 2021 Sep-Oct;42(5):102648. doi: 10.1016/j.amjoto.2020.102648. Epub 2020 Jul 14.
4
A structural equation model to examine the clinical features of mild-to-moderate COVID-19: A multicenter Italian study.采用结构方程模型探究轻度至中度 COVID-19 的临床特征:一项多中心意大利研究。
J Med Virol. 2021 Feb;93(2):983-994. doi: 10.1002/jmv.26354. Epub 2020 Aug 2.
5
Diagnostic Value of Patient-Reported and Clinically Tested Olfactory Dysfunction in a Population Screened for COVID-19.患者报告和临床测试嗅觉功能障碍在 COVID-19 筛查人群中的诊断价值。
JAMA Otolaryngol Head Neck Surg. 2021 Mar 1;147(3):271-279. doi: 10.1001/jamaoto.2020.5074.
6
Long-Term Taste and Smell Outcomes After COVID-19.新冠病毒感染后的长期味觉和嗅觉结果
JAMA Netw Open. 2024 Apr 1;7(4):e247818. doi: 10.1001/jamanetworkopen.2024.7818.
7
Prevalence of taste and smell dysfunction in mild and asymptomatic COVID-19 patients during Omicron prevalent period in Shanghai, China: a cross-sectional survey study.中国上海奥密克戎流行期间轻度和无症状 COVID-19 患者味觉和嗅觉功能障碍的患病率:一项横断面调查研究。
BMJ Open. 2023 Mar 21;13(3):e067065. doi: 10.1136/bmjopen-2022-067065.
8
Self-reported Taste and Smell Disorders in Patients with COVID-19: Distinct Features in China.新冠病毒患者自报的味觉和嗅觉障碍:中国的独特特征。
Curr Med Sci. 2021 Feb;41(1):14-23. doi: 10.1007/s11596-021-2312-7. Epub 2021 Feb 13.
9
Olfactory and Gustatory Dysfunction in Coronavirus Disease 2019 (COVID-19).2019冠状病毒病(COVID-19)中的嗅觉和味觉功能障碍
Clin Infect Dis. 2020 Nov 19;71(16):2262-2264. doi: 10.1093/cid/ciaa525.
10
Taste and Smell Disorders in COVID-19 Patients: Role of Interleukin-6.新型冠状病毒肺炎患者的味觉和嗅觉障碍:白细胞介素 6 的作用。
ACS Chem Neurosci. 2020 Sep 2;11(17):2774-2781. doi: 10.1021/acschemneuro.0c00447. Epub 2020 Aug 19.

引用本文的文献

1
Assessment of Supplementation with Different Biomolecules in the Prevention and Treatment of COVID-19.评估不同生物分子在 COVID-19 预防和治疗中的补充作用。
Nutrients. 2024 Sep 11;16(18):3070. doi: 10.3390/nu16183070.
2
Determinants of persistence and recovery of chronic coronavirus disease 2019 chemosensory dysfunction.2019年慢性冠状病毒病化学感应功能障碍持续存在和恢复的决定因素。
J Allergy Clin Immunol. 2025 Jan;155(1):120-134. doi: 10.1016/j.jaci.2024.08.027. Epub 2024 Sep 11.
3
Fukuchi-Manabe Score for Infection Control Measures During the Very Early COVID-19 Pandemic Period When Access to Reverse Transcription-Polymerase Chain Reaction Testing Was Poor in Japan: A Single-Center Observational Prospective Cohort Study.日本在新冠疫情极早期逆转录-聚合酶链反应检测条件有限时感染控制措施的福地-真锅评分:一项单中心观察性前瞻性队列研究
Cureus. 2024 Feb 23;16(2):e54748. doi: 10.7759/cureus.54748. eCollection 2024 Feb.
4
Taste loss as a distinct symptom of COVID-19: a systematic review and meta-analysis.味觉丧失是 COVID-19 的一个独特症状:系统评价和荟萃分析。
Chem Senses. 2023 Jan 1;48. doi: 10.1093/chemse/bjad043.
5
Smell, taste and chemesthesis disorders in patients with the SARS-CoV-2 during Omicron variant pandemic in China.中国奥密克戎变异株大流行期间新型冠状病毒肺炎患者的嗅觉、味觉和化学感觉障碍
Heliyon. 2023 Oct 5;9(10):e20715. doi: 10.1016/j.heliyon.2023.e20715. eCollection 2023 Oct.
6
Otolaryngology-related symptoms of COVID-19 in children in the post-epidemic era: a cross-sectional web-based survey study.后疫情时代儿童新冠病毒感染相关的耳鼻喉科症状:一项基于网络的横断面调查研究
Front Pediatr. 2023 Aug 4;11:1190734. doi: 10.3389/fped.2023.1190734. eCollection 2023.
7
Effect of any form of steroids in comparison with that of other medications on the duration of olfactory dysfunction in patients with COVID-19: A systematic review of randomized trials and quasi-experimental studies.比较任何形式的类固醇与其他药物对 COVID-19 患者嗅觉功能障碍持续时间的影响:随机试验和准实验研究的系统评价。
PLoS One. 2023 Aug 2;18(8):e0288285. doi: 10.1371/journal.pone.0288285. eCollection 2023.
8
Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial.嗅觉训练、棕榈酸乙醇酰胺和木樨草素或联合治疗 COVID-19 嗅觉功能障碍:一项盲法对照多中心随机试验。
Eur Arch Otorhinolaryngol. 2023 Nov;280(11):4949-4961. doi: 10.1007/s00405-023-08085-8. Epub 2023 Jun 28.
9
COVID-19 olfactory dysfunction, evaluation of onset, and persistence.2019冠状病毒病嗅觉功能障碍、发病情况及持续时间评估
J Adv Pharm Technol Res. 2023 Apr-Jun;14(2):137-141. doi: 10.4103/japtr.japtr_48_23. Epub 2023 Apr 13.
10
Antibody response, associated symptoms and profile of patients presumably infected by SARS-CoV-2 with taste or smell disorders in the SAPRIS multicohort study.抗体反应、相关症状以及 SAPRIS 多队列研究中味觉或嗅觉障碍疑似 SARS-CoV-2 感染患者的特征。
BMC Infect Dis. 2023 Apr 14;23(1):228. doi: 10.1186/s12879-023-08162-7.

本文引用的文献

1
Clinical Presentation of COVID-19: A Systematic Review Focusing on Upper Airway Symptoms.新型冠状病毒肺炎的临床表现:以上呼吸道症状为重点的系统评价
Ear Nose Throat J. 2020 Nov;99(9):569-576. doi: 10.1177/0145561320920762. Epub 2020 Apr 13.
2
Presentation of new onset anosmia during the COVID-19 pandemic.在 COVID-19 大流行期间出现新发嗅觉丧失。
Rhinology. 2020 Jun 1;58(3):295-298. doi: 10.4193/Rhin20.116.
3
Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study.嗅觉和味觉障碍作为冠状病毒病(COVID-19)轻至中度形式的临床特征:一项多中心欧洲研究。
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261. doi: 10.1007/s00405-020-05965-1. Epub 2020 Apr 6.
4
Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study.严重急性呼吸综合征冠状病毒2感染患者的自我报告嗅觉和味觉障碍:一项横断面研究。
Clin Infect Dis. 2020 Jul 28;71(15):889-890. doi: 10.1093/cid/ciaa330.
5
The possibility of COVID-19 transmission from eye to nose.新冠病毒从眼睛传播至鼻子的可能性。
Acta Ophthalmol. 2020 May;98(3):e388. doi: 10.1111/aos.14412. Epub 2020 Mar 18.
6
There may be virus in conjunctival secretion of patients with COVID-19.新型冠状病毒肺炎患者的结膜分泌物中可能存在病毒。
Acta Ophthalmol. 2020 May;98(3):223. doi: 10.1111/aos.14413. Epub 2020 Mar 18.
7
COVID-19 and Italy: what next?COVID-19 和意大利:下一步如何?
Lancet. 2020 Apr 11;395(10231):1225-1228. doi: 10.1016/S0140-6736(20)30627-9. Epub 2020 Mar 13.
8
Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals.新型冠状病毒病 (COVID-19) 是否会影响眼睛?对人类和动物中冠状病毒和眼部影响的综述。
Ocul Immunol Inflamm. 2020 Apr 2;28(3):391-395. doi: 10.1080/09273948.2020.1738501. Epub 2020 Mar 16.
9
Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response.意大利伦巴第大区新冠疫情期间的重症监护利用情况:应急响应中的早期经验与预测
JAMA. 2020 Apr 28;323(16):1545-1546. doi: 10.1001/jama.2020.4031.
10
Patients with RT-PCR-confirmed COVID-19 and Normal Chest CT.经逆转录聚合酶链反应(RT-PCR)确诊为新型冠状病毒肺炎(COVID-19)且胸部CT正常的患者。
Radiology. 2020 May;295(2):E3. doi: 10.1148/radiol.2020200702. Epub 2020 Mar 6.

2019 年冠状病毒病味觉和嗅觉功能障碍的流行情况。

Prevalence of Taste and Smell Dysfunction in Coronavirus Disease 2019.

机构信息

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Otorhinolaryngology Unit, Humanitas Clinical and Research Center, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Rozzano, Milan, Italy.

出版信息

JAMA Otolaryngol Head Neck Surg. 2020 Aug 1;146(8):723-728. doi: 10.1001/jamaoto.2020.1155.

DOI:10.1001/jamaoto.2020.1155
PMID:32556070
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7303892/
Abstract

IMPORTANCE

Early diagnosis of coronavirus disease 2019 (COVID-19) may help control the diffusion of the disease into the population.

OBJECTIVE

To investigate the presence of sinonasal manifestations at the onset of COVID-19 to achieve an earlier diagnosis.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective telephone survey study investigated patients diagnosed with COVID-19 from March 5 to March 23, 2020, who were hospitalized or discharged from a single referral center. Patients who were unable to answer (intubated, receiving noninvasive ventilation, or deceased) or unreachable by telephone were excluded. Of 359 consecutive patients, 204 fulfilled the inclusion criteria; 76 were unable to answer, 76 were unreachable by telephone, and 3 refused.

EXPOSURES

Sinonasal manifestations reported before COVID-19 diagnosis were studied with a validated questionnaire: Italian Sino-Nasal Outcome Test 22 (I-SNOT-22). If reduction of taste and/or smell was documented by item 5 of the I-SNOT-22, further inquiries were made to score them separately on a scale from 0 to 5, with 0 indicating no problem and 5 indicating problem as bad as it can be.

MAIN OUTCOMES AND MEASURES

The prevalence of sinonasal manifestations preceding COVID-19 diagnosis.

RESULTS

Among the 204 patients enrolled (110 [53.9%] male; mean [SD] age, 52.6 [14.4] years), the median I-SNOT-22 total score was 21 (range, 0-73). I-SNOT-22 identified 116 patients (56.9%) with reduction of taste and/or smell, 113 (55.4%) with taste reduction (median score, 5; range, 2-5), and 85 (41.7%) with smell reduction (median score, 5; range, 1-5). Eighty-two patients (40.2%) reported both. Severe reduction of taste was present in 81 patients (39.7%), and severe reduction of smell was present in 72 patients (35.3%). Only 12 patients (14.8%) with severe taste reduction and 12 patients (16.7%) with severe smell reduction reported severe nasal obstruction. Severe reduction of taste and smell was more prevalent in female vs male patients (odds ratios, 3.16 [95% CI, 1.76-5.67] vs 2.58 [95% CI, 1.43-4.65]) and middle-aged vs younger patients (effect sizes, 0.50 [95% CI, 0.21-0.78] vs 0.85 [95% CI, 0.55-1.15]). No significant association was observed between smoking habits and severe reduction of taste (odds ratio, 0.95; 95% CI, 0.53-1.71) and/or smell (odds ratio, 0.65; 95% CI, 0.35-1.21).

CONCLUSIONS AND RELEVANCE

The findings of this telephone survey study suggest that reduction of taste and/or smell may be a frequent and early symptom of COVID-19. Nasal obstruction was not commonly present at the onset of the disease in this study. The general practitioner may play a pivotal role in identifying potential COVID-19 in patients at an early stage if taste and/or smell alterations manifest and in suggesting quarantine before confirmation or exclusion of the diagnosis.

摘要

重要性

早期诊断 2019 年冠状病毒病(COVID-19)可能有助于控制疾病在人群中的传播。

目的

调查 COVID-19 发病时的鼻-鼻窦表现,以实现早期诊断。

设计、地点和参与者:本回顾性电话调查研究调查了 2020 年 3 月 5 日至 3 月 23 日期间在一家转诊中心住院或出院的 COVID-19 确诊患者。无法回答(插管、接受无创通气或死亡)或无法通过电话联系的患者被排除在外。在连续的 359 名患者中,有 204 名符合纳入标准;76 名无法回答,76 名无法通过电话联系,3 名拒绝。

暴露

使用经过验证的问卷研究 COVID-19 诊断前的鼻-鼻窦表现:意大利鼻-鼻窦结局测试 22 项(I-SNOT-22)。如果 I-SNOT-22 的第 5 项记录了味觉和/或嗅觉减退,进一步询问并在 0 到 5 的范围内单独评分,0 表示没有问题,5 表示问题非常严重。

主要结果和措施

COVID-19 诊断前鼻-鼻窦表现的患病率。

结果

在纳入的 204 名患者中(110 名[53.9%]男性;平均[SD]年龄,52.6[14.4]岁),中位数 I-SNOT-22 总分 21(范围 0-73)。I-SNOT-22 确定了 116 名(56.9%)味觉和/或嗅觉减退患者、113 名(55.4%)味觉减退患者(中位数评分 5;范围 2-5)和 85 名(41.7%)嗅觉减退患者(中位数评分 5;范围 1-5)。82 名患者(40.2%)报告同时存在两种症状。81 名患者(39.7%)味觉严重减退,72 名患者(35.3%)嗅觉严重减退。只有 12 名(14.8%)严重味觉减退和 12 名(16.7%)严重嗅觉减退患者报告严重鼻塞。女性严重味觉和嗅觉减退的比例高于男性(优势比,3.16[95%CI,1.76-5.67]与 2.58[95%CI,1.43-4.65]),中年患者高于年轻患者(效应量,0.50[95%CI,0.21-0.78]与 0.85[95%CI,0.55-1.15])。吸烟习惯与严重味觉减退(优势比,0.95;95%CI,0.53-1.71)和/或嗅觉减退(优势比,0.65;95%CI,0.35-1.21)无显著相关性。

结论和相关性

这项电话调查研究的结果表明,味觉和/或嗅觉减退可能是 COVID-19 的一种常见且早期的症状。在本研究中,疾病发作时通常没有明显的鼻塞。如果出现味觉和/或嗅觉改变,全科医生可能在早期识别出有潜在 COVID-19 的患者,并在确诊或排除该诊断之前建议隔离,从而在早期发挥关键作用。